Topic: multiple sclerosis
Even if Acorda loses its upcoming appeal on Ampyra's patents, its sales force won’t have to worry, CEO Ron Cohen says.
A new study showed Ocrevus could reduce patients' immune responses to vaccines against tetanus, seasonal flu and pneumococcus.
Embattled Celgene already bid goodbye to its COO and business development guru, and now it's moving up its executive ranks to make more changes.
Teva's restructuring and cost-cutting initiatives are clearly working, but worries about generic competition to MS blockbuster Copaxone are putting pressure on Teva to continue to innovate.
Biogen's Spinraza sales only increased modestly quarter-over-quarter, but there's still plenty of growth ahead, execs say.
Novartis hopes its MS drug siponimod’s performance can help secure a blockbuster approval. And now it has more data to back it up.
Crowding in the MS field hasn’t stopped Roche's Ocrevus from making a splash. But that competition has made it tough to snag reimbursement in England.
European regulators are recommending an immediate suspension and recall of AbbVie and Biogen multiple sclerosis drug Zinbryta.
It was a short run, but Biogen and AbbVie’s multiple sclerosis-fighter Zinbryta is coming off markets around the globe.
Putting digital into Novartis' DNA is one of CEO Vas Narasimhan’s goals, and the drugmaker has just inked another deal that aims to do just that.